Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

From the death of folk music star Peter Yarrow of Peter, Paul and Mary to good news from broadcasting legend Dick Vitale, ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Words like service and sacrifice can be used to describe firefighters. Part of their sacrifice, is their health. January is ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Folk singer-songwriter Peter Yarrow, most known as a member of the trio Peter, Paul and Mary, has died at 86 years old. The ...

The department has added several blood and urinary tract cancers to the list of diseases considered to be related to service ...

Pfizer's Phase 3 CREST trial results highlight the efficacy of sasanlimab combined with BCG in treating high-risk non-muscle invasive bladder cancer.

Chemotherapy regimen shows potential to improve survival and reduce need for surgery in patients with muscle-invasive bladder ...